Most Read Articles
10 Jan 2018
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.

Pearl Toh, 15 Dec 2017
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.

Poor insurance coverage, costs keep patients from sticking with PCSK9 inhibitors

10 Jan 2018

Researchers from Duke University in Durham, North Carolina, US, found that up to a third of patients discontinue proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor treatment due to inadequate insurance coverage. [Navar AM, et al, AHA 2017, abstract S2112]

The results were based on a web survey of nearly 800 adults who participated in pharmaceutical company-supported online patient support groups after being prescribed PCSK9 inhibitors.

Most of the participants had tried statins at some point. At the time of the survey, 31 percent of participants were on a statin, 16.7 percent were on a high-intensity statin, and 18.8 percent were taking ezetimibe.

Eighty-seven percent of respondents (n=699) began PCSK9 inhibitor therapy when prescribed. Eighty percent of these respondents received free sample medications at some point. Sixty-six percent of respondents had approved insurance coverage for treatment but while 43 percent reported no co-pay, 16.3 percent reported paying over USD 400 per month out of pocket.

Among those who began PCSK9 inhibitor therapy, 67.7 percent remained on treatment. Those who stopped did so within 1 month (9 percent), 1–3 months (36 percent), 4–6 months (15.8 percent), and after 6 months (39.2 percent), citing insurance approval or re-approval failure (30.5 percent) and high costs (25.5 percent) as reasons.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
10 Jan 2018
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.

Pearl Toh, 15 Dec 2017
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.